Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019



Summary



GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Retinal Vein Occlusion Therapeutics market. The report identifies the key trends shaping and driving the global Retinal Vein Occlusion Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Retinal Vein Occlusion Therapeutics sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



Scope


The report provides information on the key drivers and challenges of the Retinal Vein Occlusion Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Retinal Vein Occlusion Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Retinal Vein Occlusion Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Retinal Vein Occlusion Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Retinal Vein Occlusion Therapeutics market



Reasons to buy


The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Retinal Vein Occlusion Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Retinal Vein Occlusion Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Retinal Vein Occlusion Therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Retinal Vein Occlusion Therapeutics - Introduction 7
2.1 Disease Overview 7
2.1.1 Types of Retinal Vein Occlusion 7
2.2 Epidemiology 9
2.2.1 Prevalence 9
2.2.2 Incidence 10
2.2.3 Mortality/Morbidity 11
2.2.4 Sex 11
2.2.5 Age 11
2.2.6 Quality of Life 11
2.2.7 Pharmacoeconomic Burden 11
2.3 Etiology and Risk Factors 12
2.3.1 Systemic Vascular/Atherosclerotic Risk Factors in Retinal Vein Occlusion 12
2.3.2 Hematological Disorders and other Systemic Conditions 13
2.3.3 Glaucoma/Ocular Hypertension 13
2.3.4 Familial Retinal Vein Occlusion 13
2.4 Pathophysiology 13
2.5 Signs and Symptoms 14
2.5.1 Macular Edema 14
2.5.2 Neovascularization 14
2.5.3 Neovascular Glaucoma 14
2.6 Diagnosis 14
2.7 Treatment and Management Pattern 16
2.7.1 Medical Approaches for Retinal Vein Occlusion 17
2.7.2 Laser Treatment 17
2.7.3 Common Surgical Approaches for Retinal Vein Occlusion 17
2.7.4 Pharmacological Approaches for Retinal Vein Occlusion 18
2.7.5 Management of Retinal Vein Occlusion 20
2.8 Referral Pathway 21
2.9 GlobalData Pipeline Report Guidance 22
3 Retinal Vein Occlusion Therapeutics - Market Characterization 23
3.1 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Global 23
3.2 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Global 24
3.3 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The US 25
3.4 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The US 26
3.5 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - France 27
3.6 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - France 28
3.7 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Germany 29
3.8 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Germany 30
3.9 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Italy 31
3.10 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Italy 32
3.11 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Spain 33
3.12 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - Spain 34
3.13 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - The UK 35
3.14 Retinal Vein Occlusion Therapeutics Market Forecast (2011- 2019) - The UK 36
3.15 Retinal Vein Occlusion Therapeutics Market Size (2006- 2011) - Japan 37
3.16 Retinal Vein Occlusion Therapeutics Market Forecast (2010- 2019) - Japan 38
3.17 Drivers and Barriers for the Retinal Vein Occlusion Therapeutics Market 39
3.17.1 Drivers for the Retinal Vein Occlusion Therapeutics Market 39
3.17.2 Barriers for the Retinal Vein Occlusion Therapeutics Market 39
3.17.3 Opportunity and Unmet Need Analysis 40
3.18 Key Takeaway 40
4 Retinal Vein Occlusion Therapeutics - Competitive Assessment 41
4.1 Overview 41
4.2 Strategic Competitor Assessment 41
4.3 Product Profiles for the Major Marketed Products in the Retinal Vein Occlusion Therapeutics Market 42
4.3.1 Lucentis (ranibizumab) 42
4.3.2 Ozurdex (dexamethasone intravitreal implant) 43
4.3.3 Avastin (bevacizumab) 45
4.4 Key Takeaway 45
5 Retinal Vein Occlusion Therapeutics - Pipeline Assessment 46
5.1 Overview 46
5.2 Strategic Pipeline Assessment 46
5.3 Retinal Vein Occlusion Therapeutics Pipeline - Pipeline by Phase of Development 47
5.3.1 Retinal Vein Occlusion Therapeutics - Phase III Pipeline 47
5.3.2 Retinal Vein Occlusion Therapeutics - Phase II/III Pipeline 47
5.3.3 Retinal Vein Occlusion Therapeutics - Phase II Pipeline 48
5.3.4 Retinal Vein Occlusion Therapeutics - Phase I/II 48
5.4 Retinal Vein Occlusion Therapeutics Market - Pipeline by Mechanism of Action 49
5.5 Technology Trends Analytic Framework 50
5.6 Retinal Vein Occlusion Therapeutics - Promising Drugs under Clinical Development 51
5.7 Molecule Profile for Promising Drugs under Clinical Development 52
5.7.1 Eylea (aflibercept injection) 52
5.8 Key Takeaway 53
6 Retinal Vein Occlusion Therapeutics - Clinical Trials Mapping 54
6.1 Clinical Trial Mapping Overview 54
6.2 Clinical Trials by Region/Country (the US, EU5 and Japan) 54
6.3 Clinical Trials by Phase 55
6.4 Clinical Trials by Trial Status 56
6.5 Prominent Sponsors 57
6.6 Key Companies Participating in Retinal Vein Occlusion Therapeutics Clinical Trials 59
7 Strategic Assessment 60
7.1 Key Events Impacting the Future Market 60
7.2 Retinal Vein Occlusion Therapeutics: Implications for Future Market Competition 61
8 Retinal Vein Occlusion Therapeutics - Future Players 62
8.1 Introduction 62
8.2 Company Profiles 62
8.2.1 Regeneron Pharmaceuticals, Inc 62
8.2.2 Novartis AG 64
8.2.3 Roche (Genentech) 66
8.2.4 Allergan 68
9 Retinal Vein Occlusion Therapeutics - Licensing and Partnership Deals 69
10 Retinal Vein Occlusion Therapeutics - Appendix 71
10.1 Market Definitions 71
10.2 Abbreviations 71
10.3 Bibliography 72
10.4 Research Methodology 73
10.4.1 Coverage 73
10.4.2 Secondary Research 73
10.4.3 Forecasting 74
10.4.4 Primary Research 76
10.4.5 Expert Panel Validation 77
10.5 Contact Us 77
10.6 Disclaimer 77
List of Tables

1.1 List of Tables
Table 1: Prevalence Rates of Retinal Vein Occlusion by Country/Region 9
Table 2: Prevalent Pool of Retinal Vein Occlusion Patients in the Seven Major Markets 10
Table 3: Recommendations for the Management of Branch Retinal Vein Occlusion 20
Table 4: Recommendations for the Management of Central Retinal Vein Occlusion 21
Table 5: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011 23
Table 6: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019 24
Table 7: Retinal Vein Occlusion Therapeutics Market, The US, Revenue ($m), 2006- 2011 25
Table 8: Retinal Vein Occlusion Therapeutics Market, The US, Forecasts ($m), 2011- 2019 26
Table 9: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011 27
Table 10: Retinal Vein Occlusion Therapeutics Market, France, Forecasts ($m), 2011- 2019 28
Table 11: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29
Table 12: Retinal Vein Occlusion Therapeutics Market, Germany, Forecasts ($m), 2011- 2019 30
Table 13: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011 31
Table 14: Retinal Vein Occlusion Therapeutics Market, Italy, Forecasts ($m), 2011- 2019 32
Table 15: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011 33
Table 16: Retinal Vein Occlusion Therapeutics Market, Spain, Forecasts ($m), 2011- 2019 34
Table 17: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011 35
Table 18: Retinal Vein Occlusion Therapeutics Market, The UK, Forecasts ($m), 2011- 2019 36
Table 19: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011 37
Table 20: Retinal Vein Occlusion Therapeutics Market, Japan, Forecasts ($m), 2011- 2019 38
Table 21: Lucentis Phase III Clinical Trial Details 43
Table 22: Number (%) of Patients With ? 15 Letter Improvement from Baseline in Best-Corrected Visual Acuity 44
Table 23: Adverse Reactions Reported by >2% of Patients in the First Six Months 44
Table 24: Retinal Vein Occlusion Therapeutics, Phase III Pipeline, 2012 47
Table 25: Retinal Vein Occlusion Therapeutics, Phase II/III Pipeline, 2012 47
Table 26: Retinal Vein Occlusion Therapeutics, Phase II Pipeline, 2012 48
Table 27: Retinal Vein Occlusion Therapeutics, Phase I/II Pipeline, 2012 48
Table 28: RVO Therapeutics - Most Promising Drugs Under Clinical Development, 2012 51
Table 29: Eylea Phase III Clinical Trial Details 53
Table 30: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012 54
Table 31: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase, 2012 55
Table 32: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status, 2012 56
Table 33: Retinal Vein Occlusion Therapeutics, Prominent Sponsors, 2012 58
Table 34: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012 59
Table 35: Regeneron - Ophthalmology Pipeline Products, 2012 63
Table 36: Novartis - Ophthalmology Pipeline Products, 2012 65
Table 37: Roche - Ophthalmology Pipeline Products, 2012 67
Table 38: Allergan, Inc. - Ophthalmology Pipeline Products, 2012 68
Table 39: Retinal Vein Occlusion Therapeutics, Global, Deals, 2009-2011 69
List of Figures

1.2 List of Figures
Figure 1: Branch Retinal Vein Occlusion 7
Figure 2: Central Vein Retinal Occlusion 8
Figure 3: Ischemic Central Retinal Vein Occlusion 8
Figure 4: Nonischemic Central Retinal Vein Occlusion 9
Figure 5: KOL Insights, Future Trends in the Prevalence for the RVO in the US and Europe 10
Figure 6: Pharmacoeconomic Burden of Retinal Vein Occlusion 12
Figure 7: Branch Retinal Vein Occlusion in the Superotemporal Quadrant of the Right Eye 15
Figure 8: Nonperfused Central Retinal Vein Occlusion in the Left Eye 15
Figure 9: Assessment of Cardiovascular Risk in Patients with Retinal Vein Occlusion 16
Figure 10: KOL Insights, Treatment and Management Patterns 16
Figure 11: KOL Insights, Usage Patterns for the Pharmacological Treatment Options 19
Figure 12: Retinal Vein Occlusion Therapeutics Market, Global, Revenue ($m), 2006- 2011 23
Figure 13: Retinal Vein Occlusion Therapeutics Market, Global, Forecast ($m), 2011- 2019 24
Figure 14: Retinal Vein Occlusion Therapeutics Market, The US, , Revenue ($m), 2006- 2011 25
Figure 15: Retinal Vein Occlusion Therapeutics Market, The US, Forecast ($m), 2011- 2019 26
Figure 16: Retinal Vein Occlusion Therapeutics Market, France, Revenue ($m), 2006- 2011 27
Figure 17: Retinal Vein Occlusion Therapeutics Market, France, Forecast ($m), 2011- 2019 28
Figure 18: Retinal Vein Occlusion Therapeutics Market, Germany, Revenue ($m), 2006- 2011 29
Figure 19: Retinal Vein Occlusion Therapeutics Market, Germany, Forecast ($m), 2011- 2019 30
Figure 20: Retinal Vein Occlusion Therapeutics Market, Italy, Revenue ($m), 2006- 2011 31
Figure 21: Retinal Vein Occlusion Therapeutics Market, Italy, Forecast ($m), 2011- 2019 32
Figure 22: Retinal Vein Occlusion Therapeutics Market, Spain, Revenue ($m), 2006- 2011 33
Figure 23: Retinal Vein Occlusion Therapeutics Market, Spain, Forecast ($m), 2011- 2019 34
Figure 24: Retinal Vein Occlusion Therapeutics Market, The UK, Revenue ($m), 2006- 2011 35
Figure 25: Retinal Vein Occlusion Therapeutics Market, The UK, Forecast ($m), 2011- 2019 36
Figure 26: Retinal Vein Occlusion Therapeutics Market, Japan, Revenue ($m), 2006- 2011 37
Figure 27: Retinal Vein Occlusion Therapeutics Market, Japan, Forecast ($m), 2011- 2019 38
Figure 28: Opportunity and Unmet Need in the Retinal Vein Occlusion Therapeutics Market, 2012 40
Figure 29: Retinal Vein Occlusion Therapeutics, Strategic Competitor Assessment, 2012 41
Figure 30:KOL Insights, Potential Future Pipeline Assets in Retinal Vein Occlusion Therapeutics 46
Figure 31: Retinal Vein Occlusion Therapeutics - Pipeline by Phase of Development, 2012 47
Figure 32: Retinal Vein Occlusion Therapeutics, Pipeline by Mechanism of Action, 2012 49
Figure 33: Retinal Vein Occlusion Therapeutics, Technology Trends Analytics Framework, 2012 50
Figure 34: Retinal Vein Occlusion Pipeline, Technology Trends Analytics Framework, Description, 2012 51
Figure 35: Retinal Vein Occlusion Therapeutics, Clinical Trials by Country, 2012 54
Figure 36: Retinal Vein Occlusion Therapeutics, Clinical Trials by Phase (%), 2012 55
Figure 37: Retinal Vein Occlusion Therapeutics, Clinical Trials by Status (%), 2012 56
Figure 38: Retinal Vein Occlusion Therapeutics, Overall Sponsors (%), 2012 57
Figure 39: Retinal Vein Occlusion Therapeutics, Prominent Sponsors (%), 2012 58
Figure 40: Retinal Vein Occlusion Therapeutics, Global, Key Companies Participating Clinical Trials, 2012 59
Figure 41: Retinal Vein Occlusion Therapeutics Market, Drivers and Barriers, 2012 60
Figure 42: Implications for Future Market Competition in the Retinal Vein Occlusion Therapeutics Market, 2012 61
Figure 43: GlobalData Market Size Estimation 74
Figure 44: GlobalData Market Forecasting Model 76
Companies Mentioned

Regeneron Pharmaceuticals, Inc
Novartis AG
Roche (Genentech)
Allergan

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 5 369
  • Industry report
  • May 2014
  • by Firstword Pharma

Chronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until recently it has been underserved in terms of effective therapeutic options. However, a revolution in personalised and ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.